A Phase 2 interventional study of ifosfamide and mitomycin C in Pancreatic Cancer, sponsored by IRCCS San Raffaele. Terminated at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-01.
Sponsored by IRCCS San Raffaele · Phase 2, Interventional, and Treatment
RATIONALE: Drugs used in chemotherapy, such as mitomycin C and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving mitomycin C together with ifosfamide works in treating patients with metastatic pancreatic cancer.
OBJECTIVES:
OUTLINE: Patients receive mitomycin C IV on day 1 and ifosfamide IV on days 1-3. Courses repeat every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's enrollment of 21 is below the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →IRCCS San Raffaele is the lead sponsor of 443 studies on the registry; 234 are open to participants now.
Counted across the registry records on this site, refreshed daily.
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed adenocarcinoma of the pancreas
PATIENT CHARACTERISTICS:
No severe comorbidities that could compromise safety, including any of the following:
PRIOR CONCURRENT THERAPY:
2,500 mg/mq on days 1-3 every 28 days
Also known as: HOLOXAN
8 mg/mq on day 1 every 28 days
Also known as: Mutamycin
Progression-free survival at 6 months
CT scan
Time frame: every 2 months during therapy; every 3 months thereafter
Toxicity
outpatient visit
Time frame: monthly
Progression-free survival
CT scan
Time frame: every 2 months during therapy; every 3 months thereafter
Overall survival
outpatient visit or phone interview
Time frame: monthly
This study is terminated, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS San Raffaele